MX2023002038A - Composiciones y metodos para dirigirse a macrofagos asociados a tumor. - Google Patents

Composiciones y metodos para dirigirse a macrofagos asociados a tumor.

Info

Publication number
MX2023002038A
MX2023002038A MX2023002038A MX2023002038A MX2023002038A MX 2023002038 A MX2023002038 A MX 2023002038A MX 2023002038 A MX2023002038 A MX 2023002038A MX 2023002038 A MX2023002038 A MX 2023002038A MX 2023002038 A MX2023002038 A MX 2023002038A
Authority
MX
Mexico
Prior art keywords
methods
targeting moiety
compounds
compositions
present
Prior art date
Application number
MX2023002038A
Other languages
English (en)
Spanish (es)
Inventor
Faith Barnett
Original Assignee
Resolute Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resolute Science Inc filed Critical Resolute Science Inc
Publication of MX2023002038A publication Critical patent/MX2023002038A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A61K49/128—Linear polymers, e.g. dextran, inulin, PEG comprising multiple complex or complex-forming groups, being either part of the linear polymeric backbone or being pending groups covalently linked to the linear polymeric backbone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2023002038A 2020-08-21 2021-08-20 Composiciones y metodos para dirigirse a macrofagos asociados a tumor. MX2023002038A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063068904P 2020-08-21 2020-08-21
PCT/US2021/046984 WO2022040580A1 (en) 2020-08-21 2021-08-20 Compositions and methods for targeting tumor-associated macrophages

Publications (1)

Publication Number Publication Date
MX2023002038A true MX2023002038A (es) 2023-05-08

Family

ID=80350585

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002038A MX2023002038A (es) 2020-08-21 2021-08-20 Composiciones y metodos para dirigirse a macrofagos asociados a tumor.

Country Status (10)

Country Link
US (1) US20240009314A1 (cg-RX-API-DMAC10.html)
EP (1) EP4199936A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023538134A (cg-RX-API-DMAC10.html)
KR (1) KR20230058086A (cg-RX-API-DMAC10.html)
CN (1) CN116723846A (cg-RX-API-DMAC10.html)
AU (1) AU2021327392A1 (cg-RX-API-DMAC10.html)
CA (1) CA3192041A1 (cg-RX-API-DMAC10.html)
IL (1) IL300787A (cg-RX-API-DMAC10.html)
MX (1) MX2023002038A (cg-RX-API-DMAC10.html)
WO (1) WO2022040580A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024224138A1 (en) * 2023-02-22 2025-08-14 Resolute Science, Inc. Compositions and methods for targeting tumor-associated macrophages
KR20250151447A (ko) * 2023-02-22 2025-10-21 레졸루트 사이언스, 인크. 종양-관련 대식세포를 표적화하기 위한 조성물 및 방법
WO2024178142A1 (en) * 2023-02-22 2024-08-29 Resolute Science, Inc. Compositions and methods for targeting tumor-associated macrophages
WO2024178140A1 (en) * 2023-02-22 2024-08-29 Resolute Science, Inc. Compositions and methods for targeting tumor-associated macrophages
WO2025029126A1 (ko) * 2023-08-03 2025-02-06 최종훈 산소가 담지된 나노리포좀 및 이의 용도
CN117503760A (zh) * 2023-10-20 2024-02-06 深圳大学 靶向kras g-四链体的吲哚类小分子在制备治疗三阴性乳腺癌药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6409990B1 (en) * 1999-05-14 2002-06-25 The Regents Of The University Of California Macromolecular carrier for drug and diagnostic agent delivery
CA2955438C (en) * 2014-07-17 2024-07-02 Ohio State Innovation Foundation DEXTRANE CONJUGATES TO TARGET MACROPHAGES AND OTHER CELLS EXPRESSING THE D-MANBOSE BINDING TYPE C LECTIN RECEPTOR
US20180021456A1 (en) * 2015-02-04 2018-01-25 University Of South Florida Self-assembled targeted inclusion complexes for drug delivery
CN105343900B (zh) * 2015-09-16 2019-04-02 中国海洋大学 褐藻多糖为载体的淋巴靶向核磁造影剂及制备方法和应用
US20170333304A1 (en) * 2016-05-20 2017-11-23 Massachusetts Institute Of Technology Hydrogel Particles, Compositions, and Methods
WO2018068060A1 (en) * 2016-10-07 2018-04-12 Navidea Biopharmaceuticals, Inc. Compounds and methods for diagnosis and treatment of viral infections
TWI804499B (zh) * 2017-06-23 2023-06-11 美商維洛斯生物公司 Ror1抗體免疫接合物
WO2019018815A1 (en) * 2017-07-21 2019-01-24 Navidea Biopharmaceuticals, Inc. USE OF 99MTC-TILMANOCEPT AND ASSOCIATED MOLECULAR CONSTRUCTS FOR THE IDENTIFICATION AND DIAGNOSIS OF MALIGNANT TUMORS, AND FOR THE MONITORING OF ANTI-TUMOR THERAPEUTIC INTERVENTIONS
WO2020018434A1 (en) * 2018-07-17 2020-01-23 Scripps Health Compositions and methods for disrupting a macrophage network
US20210052639A1 (en) * 2019-08-19 2021-02-25 Navidea Biopharmaceuticals, Inc. Compositions and related methods for the ablation of m2 macrophages and myeloid derived suppressor cells
WO2021067479A1 (en) * 2019-09-30 2021-04-08 Navidea Biopharmaceuticals, Inc. Compositions and related methods for blocking off-target localization of mannosylated dextrans and other cd206 ligands
US11859023B2 (en) * 2020-07-08 2024-01-02 Navidea Biopharmaceuticals, Inc. Synthesis of uniformly defined molecular weight mannosylated dextrans and derivatives thereof

Also Published As

Publication number Publication date
CA3192041A1 (en) 2022-02-24
IL300787A (en) 2023-04-01
US20240009314A1 (en) 2024-01-11
KR20230058086A (ko) 2023-05-02
CN116723846A (zh) 2023-09-08
AU2021327392A1 (en) 2023-04-27
AU2021327392A9 (en) 2024-08-01
WO2022040580A1 (en) 2022-02-24
EP4199936A4 (en) 2025-05-07
EP4199936A1 (en) 2023-06-28
JP2023538134A (ja) 2023-09-06

Similar Documents

Publication Publication Date Title
MX2023013592A (es) Conjugados de farmaco con enlazadores autoestabilizantes que tienen propiedades fisioquimicas mejoradas.
MX2021005389A (es) Formulaciones de nanoparticulas lipidicas.
EA201991692A1 (ru) Иммуносконструированные плюрипотентные клетки
CO2023004252A2 (es) Anticuerpos anti-ceacam5 y conjugados y usos de los mismos
MX2022006033A (es) Lipidos ionizables y composiciones de nanoparticulas de estos.
MX2020001734A (es) Derivados de 6-amino-7,9-dihidro-8h-purina-8-ona como agonistas inmunoestimulantes del receptor 7 tipo toll (tlr7).
MX2020001475A (es) Derivados de 6-amino-7,9-dihidro-8h-purin-8-ona como agonistas del receptor 7 tipo toll (tlr7) inmunoestimulantes.
AU2018338608A1 (en) Methods, compositions, and implantable elements comprising active cells
MX2023000835A (es) Formulaciones del esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso de este.
EA201201400A1 (ru) Композиции и способы лечения аутоиммунных и других заболеваний
MX2020001603A (es) Derivados de 6-amino-7,9-dihidro-8h-purin-8-ona como agonistas del receptor 7 del tipo toll (tlr7) como inmunoestimulantes.
EA201200939A1 (ru) Липиды, липидные композиции и способы их применения
MX2021015974A (es) Conjugados de anticuerpos y farmacos anti-factor tisular y metodos relacionados.
WO2022183074A3 (en) Anti-psma antibodies and car-t structures
EA201990890A1 (ru) Целевая доставка ингибиторов реутилизационного пути никотинамидадениндинуклеотида
CO6470821A2 (es) Pirazinilpirazoles
EP3804725A3 (en) Nanomaterial compositions, synthesis, and assembly
CY1118044T1 (el) Παρασκευασμα συνδυασμου με ανταγωνιστη και κορτικοστεροειδες
MX2019007626A (es) Producto para el cuidado bucal y metodos de uso y fabricacion de este.
BR112022002720A2 (pt) Formulações de conjugados de benzazepinas e usos das mesmas
UY29639A1 (es) Amidas sustituidas con heteroarilo que comprenden un grupo enlazador insaturado o cíclico, y su uso como productos farmacéuticos
MX2025002929A (es) Compuestos de objetivo brm y metodos de uso asociados
MX2021005756A (es) Dendrimero terapeutico.
MX2020012107A (es) Composiciones y procedimientos para el tratamiento del cancer.
BR112023002301A2 (pt) Anticorpos contra ilt2 e uso dos mesmos